In Brief: Quidel/Ansell correction
This article was originally published in The Gray Sheet
Executive Summary
Quidel/Ansell correction: In a release announcing Quidel's distribution and marketing agreement with Ansell Consumer Products ("The Gray Sheet" Nov. 20, I&W-7), Ansell incorrectly stated that the three Quidel pregnancy tests involved in the agreement -- Conceive, Q-Test, and RapidVue -- would be sold under Ansell's Lifestyles brand with coupons for Lifestyles condoms. In fact, only the RapidVue test will be sold under the Lifestyles name with coupons...You may also be interested in...
‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney
Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.
HBW Market News: GNC US Chief, Clasado Commercial Head, Barentz Funding
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
US Government Drug Pricing ‘Negotiation:’ Where We Go From Here
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: